International Journal of Colorectal Disease · 2018 · 11 citations · 34 references
MedicinePharmacoeconomicsCost-effectiveness AnalysisCost-minimization AnalysisPain MedicineBowel Function AssessmentConstipation ManagementFunctional Gastrointestinal DisordersIrritable Bowel SyndromeBudget Impact PerspectiveDirect Treatment CostsIrritable Bowel Syndrome ComorbidityMedication Budget ImpactObstructed DefecationRefractory Constipation ManagementRome CriteriaSlow Transit Constipation Treatment
PURPOSE: The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment. METHODS: This study is an open-label, multicenter randomized controlled trial. Patients aged 14 to 80 with slow-transit constipation, a defecation frequency (DF) < 3 per week and meeting at least one other Rome-IV criterion, are eligible. Patients with obstructed outlet, irritable bowel syndrome, bowel pathology, or rectal prolapse are excluded. Patients are randomized to SNM or PCT. The primary outcome is success at 6 months (DF ≥ 3 a week), requiring a sample size of 64 (α = 0.05, β = 0.80, 30% difference in success). Secondary outcomes are straining, sense of incomplete evacuation, constipation severity, fatigue, constipation specific and generic quality of life, and costs at 6 months. Long-term costs and effectiveness will be estimated by a decision analytic model. The time frame is 57 months, starting October 2016. SNM treatment costs are funded by the Dutch conditional reimbursement program, research costs by Medtronic. CONCLUSIONS: The results of this trial will be used to make a final decision regarding reimbursement of SNM from the Dutch Health Care Package in this patient group. TRIAL REGISTRATION: This trial is registered at clinicaltrials.gov , identifier NCT02961582, on 12 October 2016.
34
Classification of Surgical Complications
Daniel Dindo, Nicolas Demartines, Pierre-Alain Clavien · Annals of Surgery · 2004 · 30.9K citations · Full text
Medicine, Surgery, General Surgery +13
The Clavien-Dindo Classification of Surgical Complications
Pierre A. Clavien, Jeffrey Barkun, Michelle Oliveira et al. · Annals of Surgery · 2009 · 11.3K citations
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text
Brian E. Lacy, Fermín Mearin, Lin Chang et al. · Gastroenterology · 2016 · 2.8K citations · Full text
Childhood Functional Gastrointestinal Disorders: Child/Adolescent
Andrée Rasquin, David Forbes, Ernesto Guiraldes et al. · Gastroenterology · 2006 · 1.8K citations · Full text
Medicine, Child Health, Pediatrics +12